Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

NewAmsterdam Pharma Co N.V.

NASDAQ: NAMS · Life Sciences · 5 alerts · CIK 1936258

Share price
$19.46Close, Nov 16
Market cap
$2.33B
Shares outstanding
119.93MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All NewAmsterdam Pharma Co N.V. filings on SEC EDGAR ↗

7:41 AM ET 10-Q
Financial Results

NewAmsterdam Pharma Co Q3 2026 Results: Net Loss of $17.4M, Loss Narrows

NewAmsterdam Pharma reported a net loss of $130.0 million for the nine months ended September 30, 2026, compared to $128.9 million in the prior year period. Revenue increased significantly to $25.9 million, primarily driven by $19.2 million in the third quarter, while the company maintained a strong liquidity position with $423.1 million in cash and cash equivalents.

Key figure
Net loss $17.4M
7:35 AM ET 8-K
Financial Results

NewAmsterdam Pharma Co Financial Results

NewAmsterdam Pharma reported third quarter 2026 financial results and highlighted the European Commission's approval of Ubeslo and Evlarco for hypercholesterolaemia. The company ended the quarter with $643.1 million in cash and expects an interim analysis of its PREVAIL cardiovascular outcomes trial in Q4 2026.

“The third quarter was marked by significant progress across our regulatory and clinical priorities, including the first regulatory approval of obicetrapib worldwide and the initiation of the SPINOZA Phase 2b trial in preclinical Alzheimer’s disease. Looking ahead, we anticipate reaching the predefined event number for the planned PREVAIL interim analysis in the fourth quarter, with the outcome expected in the first quarter of 2027.”

Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam Pharma

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.